Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Vertex Pharmaceuticals Inc
Operating Income
Vertex Pharmaceuticals Inc
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Operating Income
$3.8B
|
CAGR 3-Years
10%
|
CAGR 5-Years
42%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Operating Income
$16.6B
|
CAGR 3-Years
8%
|
CAGR 5-Years
7%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Operating Income
$8.7B
|
CAGR 3-Years
24%
|
CAGR 5-Years
1%
|
CAGR 10-Years
3%
|
|
Amgen Inc
NASDAQ:AMGN
|
Operating Income
$8.2B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
3%
|
|
Moderna Inc
NASDAQ:MRNA
|
Operating Income
-$4.2B
|
CAGR 3-Years
-77%
|
CAGR 5-Years
-59%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Operating Income
$4.2B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
19%
|
See Also
What is Vertex Pharmaceuticals Inc's Operating Income?
Operating Income
3.8B
USD
Based on the financial report for Dec 31, 2023, Vertex Pharmaceuticals Inc's Operating Income amounts to 3.8B USD.
What is Vertex Pharmaceuticals Inc's Operating Income growth rate?
Operating Income CAGR 5Y
42%
Over the last year, the Operating Income growth was -11%. The average annual Operating Income growth rates for Vertex Pharmaceuticals Inc have been 10% over the past three years , 42% over the past five years .